share_log

復星醫藥:董事會會議日期

FOSUN PHARMA: DATE OF BOARD MEETING

Hong Kong Stock Exchange ·  Aug 12 05:09
Summary by Moomoo AI
上海復星醫藥(集團)股份有限公司(「復星醫藥」)將於2024年8月27日(星期二)召開董事會會議,屆時將考慮及通過該公司及其附屬公司截至2024年6月30日止六個月的中期業績並予以公布。復星醫藥的執行董事包括吳以芳先生、王可心先生、關曉暉女士及文德鏞先生;非執行董事為陳啟宇先生、徐曉亮先生及潘東輝先生;獨立非執行董事則包括李玲女士、湯谷良先生、王全弟先生及余梓山先生。會議的具體內容將涉及中期業績的審核與批准,這對投資者而言是一項重要的財務信息更新。
上海復星醫藥(集團)股份有限公司(「復星醫藥」)將於2024年8月27日(星期二)召開董事會會議,屆時將考慮及通過該公司及其附屬公司截至2024年6月30日止六個月的中期業績並予以公布。復星醫藥的執行董事包括吳以芳先生、王可心先生、關曉暉女士及文德鏞先生;非執行董事為陳啟宇先生、徐曉亮先生及潘東輝先生;獨立非執行董事則包括李玲女士、湯谷良先生、王全弟先生及余梓山先生。會議的具體內容將涉及中期業績的審核與批准,這對投資者而言是一項重要的財務信息更新。
Fosun Pharma Group Limited, Shanghai ("Board of Directors") will hold a board of directors meeting on Tuesday, August 27, 2024 to consider and approve the company and its subsidiaries' mid-year performance for the six months ended June 30, 2024 and disclose it. Fosun Pharma's executive directors include Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui, and Mr. Wen Deyong; non-executive directors are Mr. Chen Qiyu, Mr. Xu Xiaoliang, and Mr. Pan Donghui; independent non-executive directors include Ms. Li Ling, Mr. Tang Guiliang, Mr. Wang Quandi, and Mr. Yu Zishan. The specific content of the meeting will involve the review and approval of mid-term performance, which is an important financial information update for investors.
Fosun Pharma Group Limited, Shanghai ("Board of Directors") will hold a board of directors meeting on Tuesday, August 27, 2024 to consider and approve the company and its subsidiaries' mid-year performance for the six months ended June 30, 2024 and disclose it. Fosun Pharma's executive directors include Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui, and Mr. Wen Deyong; non-executive directors are Mr. Chen Qiyu, Mr. Xu Xiaoliang, and Mr. Pan Donghui; independent non-executive directors include Ms. Li Ling, Mr. Tang Guiliang, Mr. Wang Quandi, and Mr. Yu Zishan. The specific content of the meeting will involve the review and approval of mid-term performance, which is an important financial information update for investors.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more